The Role of Echocardiography in Cardio-oncology Patients: Contemporary Indications and Future Directions

Saiuj Bhat, Nestor Gahungu, Paaladinesh Thavendiranathan, Girish Dwivedi

Research output: Contribution to journalReview article

Abstract

Purpose of Review: This review discusses the latest advances, guideline recommendations, and limitations of the use of echocardiography in evaluation of cancer therapeutics–related cardiac dysfunction (CTRCD) and highlights advances in cardio-oncology that have the potential to augment the echocardiographic assessment of CTRCD. Recent Findings: Cardio-oncology is a rapidly evolving field aimed at improving the quality of life of cancer patients by preventing and treating the adverse cardiovascular complications of cancer therapy. Cardiac imaging tools, in particular transthoracic echocardiography, play a pivotal role in the early detection and monitoring of CTRCD. Recent studies have indicated the potential benefit of a number of echocardiographic parameters in addition to left ventricular ejection fraction in the evaluation of CTRCD. Summary: We anticipate that echocardiography will continue to play a central role in the field of cardio-oncology over the coming years. The utility and predictive value of echocardiographic indices will continue to improve with advances in imaging technology and development of novel biomarkers to supplement imaging parameters. Ensuring equitable and easy access to cardio-oncology services, especially in remote and disadvantaged communities, remains an area of ongoing investigation and will undoubtedly be assisted with new innovations in image acquisition, transmission, and analysis. Lastly, machine learning is likely to revolutionise the evaluation of CTRCD in light of the rapid progress of artificial intelligence–driven automation for the analysis and interpretation of echocardiograms.

Original languageEnglish
Article number42
JournalCurrent Cardiovascular Imaging Reports
Volume12
Issue number12
DOIs
Publication statusPublished - 1 Dec 2019

Fingerprint

Heart Neoplasms
Echocardiography
Automation
Vulnerable Populations
Early Detection of Cancer
Stroke Volume
Neoplasms
Biomarkers
Quality of Life
Guidelines
Technology
Direction compound
Therapeutics

Cite this

@article{28805e79308246c4b7ad048460dc0fea,
title = "The Role of Echocardiography in Cardio-oncology Patients: Contemporary Indications and Future Directions",
abstract = "Purpose of Review: This review discusses the latest advances, guideline recommendations, and limitations of the use of echocardiography in evaluation of cancer therapeutics–related cardiac dysfunction (CTRCD) and highlights advances in cardio-oncology that have the potential to augment the echocardiographic assessment of CTRCD. Recent Findings: Cardio-oncology is a rapidly evolving field aimed at improving the quality of life of cancer patients by preventing and treating the adverse cardiovascular complications of cancer therapy. Cardiac imaging tools, in particular transthoracic echocardiography, play a pivotal role in the early detection and monitoring of CTRCD. Recent studies have indicated the potential benefit of a number of echocardiographic parameters in addition to left ventricular ejection fraction in the evaluation of CTRCD. Summary: We anticipate that echocardiography will continue to play a central role in the field of cardio-oncology over the coming years. The utility and predictive value of echocardiographic indices will continue to improve with advances in imaging technology and development of novel biomarkers to supplement imaging parameters. Ensuring equitable and easy access to cardio-oncology services, especially in remote and disadvantaged communities, remains an area of ongoing investigation and will undoubtedly be assisted with new innovations in image acquisition, transmission, and analysis. Lastly, machine learning is likely to revolutionise the evaluation of CTRCD in light of the rapid progress of artificial intelligence–driven automation for the analysis and interpretation of echocardiograms.",
keywords = "Cancer, Cardio-oncology, Chemotherapy, Echocardiography, Imaging",
author = "Saiuj Bhat and Nestor Gahungu and Paaladinesh Thavendiranathan and Girish Dwivedi",
year = "2019",
month = "12",
day = "1",
doi = "10.1007/s12410-019-9519-z",
language = "English",
volume = "12",
journal = "Current Cardiovascular Imaging Reports",
issn = "1941-9066",
publisher = "Current Medicine Group",
number = "12",

}

The Role of Echocardiography in Cardio-oncology Patients : Contemporary Indications and Future Directions. / Bhat, Saiuj; Gahungu, Nestor; Thavendiranathan, Paaladinesh; Dwivedi, Girish.

In: Current Cardiovascular Imaging Reports, Vol. 12, No. 12, 42, 01.12.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The Role of Echocardiography in Cardio-oncology Patients

T2 - Contemporary Indications and Future Directions

AU - Bhat, Saiuj

AU - Gahungu, Nestor

AU - Thavendiranathan, Paaladinesh

AU - Dwivedi, Girish

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Purpose of Review: This review discusses the latest advances, guideline recommendations, and limitations of the use of echocardiography in evaluation of cancer therapeutics–related cardiac dysfunction (CTRCD) and highlights advances in cardio-oncology that have the potential to augment the echocardiographic assessment of CTRCD. Recent Findings: Cardio-oncology is a rapidly evolving field aimed at improving the quality of life of cancer patients by preventing and treating the adverse cardiovascular complications of cancer therapy. Cardiac imaging tools, in particular transthoracic echocardiography, play a pivotal role in the early detection and monitoring of CTRCD. Recent studies have indicated the potential benefit of a number of echocardiographic parameters in addition to left ventricular ejection fraction in the evaluation of CTRCD. Summary: We anticipate that echocardiography will continue to play a central role in the field of cardio-oncology over the coming years. The utility and predictive value of echocardiographic indices will continue to improve with advances in imaging technology and development of novel biomarkers to supplement imaging parameters. Ensuring equitable and easy access to cardio-oncology services, especially in remote and disadvantaged communities, remains an area of ongoing investigation and will undoubtedly be assisted with new innovations in image acquisition, transmission, and analysis. Lastly, machine learning is likely to revolutionise the evaluation of CTRCD in light of the rapid progress of artificial intelligence–driven automation for the analysis and interpretation of echocardiograms.

AB - Purpose of Review: This review discusses the latest advances, guideline recommendations, and limitations of the use of echocardiography in evaluation of cancer therapeutics–related cardiac dysfunction (CTRCD) and highlights advances in cardio-oncology that have the potential to augment the echocardiographic assessment of CTRCD. Recent Findings: Cardio-oncology is a rapidly evolving field aimed at improving the quality of life of cancer patients by preventing and treating the adverse cardiovascular complications of cancer therapy. Cardiac imaging tools, in particular transthoracic echocardiography, play a pivotal role in the early detection and monitoring of CTRCD. Recent studies have indicated the potential benefit of a number of echocardiographic parameters in addition to left ventricular ejection fraction in the evaluation of CTRCD. Summary: We anticipate that echocardiography will continue to play a central role in the field of cardio-oncology over the coming years. The utility and predictive value of echocardiographic indices will continue to improve with advances in imaging technology and development of novel biomarkers to supplement imaging parameters. Ensuring equitable and easy access to cardio-oncology services, especially in remote and disadvantaged communities, remains an area of ongoing investigation and will undoubtedly be assisted with new innovations in image acquisition, transmission, and analysis. Lastly, machine learning is likely to revolutionise the evaluation of CTRCD in light of the rapid progress of artificial intelligence–driven automation for the analysis and interpretation of echocardiograms.

KW - Cancer

KW - Cardio-oncology

KW - Chemotherapy

KW - Echocardiography

KW - Imaging

UR - http://www.scopus.com/inward/record.url?scp=85075205244&partnerID=8YFLogxK

U2 - 10.1007/s12410-019-9519-z

DO - 10.1007/s12410-019-9519-z

M3 - Review article

VL - 12

JO - Current Cardiovascular Imaging Reports

JF - Current Cardiovascular Imaging Reports

SN - 1941-9066

IS - 12

M1 - 42

ER -